Diagnosis requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation. A platform can help align a team of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs. Treatment and management of cardiomyopathy requires individual development, typically including a lack of pharmacotherapy, rehabilitation interventions, regular follow-up, etc.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat genetic metabolic diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule of disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of cardiomyopathy associated with carcinogenicity.
The platform serves China's international medical service system, a team of nationally and internationally authoritative experts in the field of genetic metabolism, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.